TY - JOUR
T1 - Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4)
T2 - an unmasked randomised controlled trial
AU - TASMINH4 investigators
AU - McManus, Richard J.
AU - Mant, Jonathan
AU - Franssen, Marloes
AU - Nickless, Alecia
AU - Schwartz, Claire
AU - Hodgkinson, James
AU - Bradburn, Peter
AU - Farmer, Andrew
AU - Grant, Sabrina
AU - Greenfield, Sheila M.
AU - Heneghan, Carl
AU - Jowett, Susan
AU - Martin, Una
AU - Milner, Siobhan
AU - Monahan, Mark
AU - Mort, Sam
AU - Ogburn, Emma
AU - Perera-Salazar, Rafael
AU - Shah, Syed Ahmar
AU - Yu, Ly Mee
AU - Tarassenko, Lionel
AU - Hobbs, F. D.Richard
AU - Bradley, Brendan
AU - Lovekin, Chris
AU - Judge, David
AU - Castello, Luis
AU - Dawson, Maureen
AU - Brice, Rebecca
AU - Dunbabin, Bethany
AU - Maslen, Sophie
AU - Rutter, Heather
AU - Norris, Mary
AU - French, Lauren
AU - Loynd, Michael
AU - Whitbread, Pippa
AU - Saldana Ortaga, Luisa
AU - Noel, Irene
AU - Madronal, Karen
AU - Timmins, Julie
AU - Bradburn, Peter
AU - Hughes, Lucy
AU - Hinks, Beth
AU - Bailey, Sheila
AU - Read, Sue
AU - Weston, Andrea
AU - Spannuth, Somi
AU - Maiden, Sue
AU - Chermahini, Makiko
AU - McDonald, Ann
AU - Buckley, David
N1 - Funding Information:
The authors acknowledge the support of the Primary Care Clinical Trials Unit Oxford. Karen Biddle and Carla Betts provided additional administrative support. David Yeomans and Derek Shaw served as patient representatives for the trial management and steering groups. Oliver Gibson developed a previous system for telemonitoring that was helpful in the development of the current system, and Carmelo Velardo and Mauro Santos provided technical support. Additional members of the trial steering group were Mike Moore (chair), Pip Logan, and Chris Clark. Members of the data monitoring committee were Martyn Lewis (chair), Emma Bray, and Sarah Purdy. The trial was funded by an National Institute for Health Research (NIHR) Programme grant (RP-PG-1209-10051), and by an NIHR Professorship awarded to RJM, the Chief Investigator (NIHR-RP-R2-12-015). Omron Healthcare UK provided the blood pressure self-monitoring equipment via an unrestricted grant. Service support costs were administered through the NIHR Clinical Research Network: West Midlands. FDRH, JM, and AF are NIHR Senior Investigators. RJM and FDRH receive support from NIHR Oxford Collaboration for Leadership in Applied Health Research and Care. FDRH is also partly supported as an NIHR Senior Investigator, Director of the NIHR School for Primary Care Research, Theme Leader of the NIHR Oxford Biomedical Research Centre, and NIHR Oxford Diagnostic Evidence Co-operative. This Article presents independent research commissioned by the NIHR under a Programme Grant for Applied Research (RP-PG-1209-10051). The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health. The sponsor was Oxford University.
Publisher Copyright:
© 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2018/3/10
Y1 - 2018/3/10
N2 - Background: Studies evaluating titration of antihypertensive medication using self-monitoring give contradictory findings and the precise place of telemonitoring over self-monitoring alone is unclear. The TASMINH4 trial aimed to assess the efficacy of self-monitored blood pressure, with or without telemonitoring, for antihypertensive titration in primary care, compared with usual care. Methods: This study was a parallel randomised controlled trial done in 142 general practices in the UK, and included hypertensive patients older than 35 years, with blood pressure higher than 140/90 mm Hg, who were willing to self-monitor their blood pressure. Patients were randomly assigned (1:1:1) to self-monitoring blood pressure (self-montoring group), to self-monitoring blood pressure with telemonitoring (telemonitoring group), or to usual care (clinic blood pressure; usual care group). Randomisation was by a secure web-based system. Neither participants nor investigators were masked to group assignment. The primary outcome was clinic measured systolic blood pressure at 12 months from randomisation. Primary analysis was of available cases. The trial is registered with ISRCTN, number ISRCTN 83571366. Findings: 1182 participants were randomly assigned to the self-monitoring group (n=395), the telemonitoring group (n=393), or the usual care group (n=394), of whom 1003 (85%) were included in the primary analysis. After 12 months, systolic blood pressure was lower in both intervention groups compared with usual care (self-monitoring, 137·0 [SD 16·7] mm Hg and telemonitoring, 136·0 [16·1] mm Hg vs usual care, 140·4 [16·5]; adjusted mean differences vs usual care: self-monitoring alone, −3·5 mm Hg [95% CI −5·8 to −1·2]; telemonitoring, −4·7 mm Hg [–7·0 to −2·4]). No difference between the self-monitoring and telemonitoring groups was recorded (adjusted mean difference −1·2 mm Hg [95% CI −3·5 to 1·2]). Results were similar in sensitivity analyses including multiple imputation. Adverse events were similar between all three groups. Interpretation: Self-monitoring, with or without telemonitoring, when used by general practitioners to titrate antihypertensive medication in individuals with poorly controlled blood pressure, leads to significantly lower blood pressure than titration guided by clinic readings. With most general practitioners and many patients using self-monitoring, it could become the cornerstone of hypertension management in primary care. Funding: National Institute for Health Research via Programme Grant for Applied Health Research (RP-PG-1209-10051), Professorship to RJM (NIHR-RP-R2-12-015), Oxford Collaboration for Leadership in Applied Health Research and Care, and Omron Healthcare UK.
AB - Background: Studies evaluating titration of antihypertensive medication using self-monitoring give contradictory findings and the precise place of telemonitoring over self-monitoring alone is unclear. The TASMINH4 trial aimed to assess the efficacy of self-monitored blood pressure, with or without telemonitoring, for antihypertensive titration in primary care, compared with usual care. Methods: This study was a parallel randomised controlled trial done in 142 general practices in the UK, and included hypertensive patients older than 35 years, with blood pressure higher than 140/90 mm Hg, who were willing to self-monitor their blood pressure. Patients were randomly assigned (1:1:1) to self-monitoring blood pressure (self-montoring group), to self-monitoring blood pressure with telemonitoring (telemonitoring group), or to usual care (clinic blood pressure; usual care group). Randomisation was by a secure web-based system. Neither participants nor investigators were masked to group assignment. The primary outcome was clinic measured systolic blood pressure at 12 months from randomisation. Primary analysis was of available cases. The trial is registered with ISRCTN, number ISRCTN 83571366. Findings: 1182 participants were randomly assigned to the self-monitoring group (n=395), the telemonitoring group (n=393), or the usual care group (n=394), of whom 1003 (85%) were included in the primary analysis. After 12 months, systolic blood pressure was lower in both intervention groups compared with usual care (self-monitoring, 137·0 [SD 16·7] mm Hg and telemonitoring, 136·0 [16·1] mm Hg vs usual care, 140·4 [16·5]; adjusted mean differences vs usual care: self-monitoring alone, −3·5 mm Hg [95% CI −5·8 to −1·2]; telemonitoring, −4·7 mm Hg [–7·0 to −2·4]). No difference between the self-monitoring and telemonitoring groups was recorded (adjusted mean difference −1·2 mm Hg [95% CI −3·5 to 1·2]). Results were similar in sensitivity analyses including multiple imputation. Adverse events were similar between all three groups. Interpretation: Self-monitoring, with or without telemonitoring, when used by general practitioners to titrate antihypertensive medication in individuals with poorly controlled blood pressure, leads to significantly lower blood pressure than titration guided by clinic readings. With most general practitioners and many patients using self-monitoring, it could become the cornerstone of hypertension management in primary care. Funding: National Institute for Health Research via Programme Grant for Applied Health Research (RP-PG-1209-10051), Professorship to RJM (NIHR-RP-R2-12-015), Oxford Collaboration for Leadership in Applied Health Research and Care, and Omron Healthcare UK.
UR - http://www.scopus.com/inward/record.url?scp=85043235084&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043235084&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(18)30309-X
DO - 10.1016/S0140-6736(18)30309-X
M3 - Article
C2 - 29499873
AN - SCOPUS:85043235084
SN - 0140-6736
VL - 391
SP - 949
EP - 959
JO - The Lancet
JF - The Lancet
IS - 10124
ER -